middle.news
Paradigm Biopharma Advances Phase 3 Trial, Secures $50M Funding Runway
9:48am on Thursday 30th of October, 2025 AEDT
•
Healthcare
Read Story
Paradigm Biopharma Advances Phase 3 Trial, Secures $50M Funding Runway
9:48am on Thursday 30th of October, 2025 AEDT
Key Points
Phase 3 dosing commenced in Australia and US for injectable PPS
Improved screening rates following FDA protocol refinements
Cash reserves of A$19.68m plus A$30.29m convertible note facility
Acquisition of Proteobioactives secures global IP for Pentacoxib™
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Paradigm Biopharmaceuticals (ASX:PAR)
OPEN ARTICLE